University of Southern California School of Pharmacy signed an agreement with China Freeze Holdings to Jointly built China Neuroscience Rehabilitation Center
On March 23，an agreement was signed in Dean’s office of USC School of Pharmacy between the School of Pharmacy and China Freeze Holdings Co., Ltd to jointly build the China Neuroscience Rehabilitation Center. Vassilios Papadopoulos, PhD, Dean of USC School of Pharmacy; Jing Liang, MD PhD, Professor, USC School of Pharmacy; Daryl L. Davies, PhD, Professor, USC School of Pharmacy; Michael Jakowec, MD, Professor, a renown neurologist, USC School of Medicine; Ke Zhang, vice president of Freeze Holdings; Huijue Yin, MD, Chief Doctor, Professor of Cardiology, renown scientist in Cardiovascular field attended the ceremony.
Today, elderly citizen population has been growing rapidly in the society of all countries in the world. In 2017, the proportion of the population of aged 65 or above was 17.3% in the United States, 25% in Japan, 14.3% in China. By 2050, the elderly population is expected to reach 480 million, 25% of China’s total population. With the increasing aging population, the diseases of central nervous systems are on the rise. In 2017 alone, there were about 13 million stroke patients in China resulting in financial burden as high as 40 billion Yuan. Therefore, the health care of the elderly is a critical issue and concern of the Chinese government.
Under this context, the China Neuroscience Rehabilitation Center came into being. The Center will be based on the world’s leading neurological rehabilitation treatment technology of the University of Southern California School of Medicine and School of Pharmacy. It will introduce the rehabilitation and medical care systems for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and stroke to the China Center.
The University of Southern California is one of the top organizations for the study of central nervous systems in the United States. Professor Davis, a well-known neuropharmacologist and director of the Department of Clinical Pharmacy at Southern California School of Pharmacy, said: “We have been paying attention to the epidemiology of neurological disorders in the elderly in China and local treatment methods. We hope that through the collaboration with Freeze Holdings, we will introduce the most advanced rehabilitation and medical care systems from the University of Southern California to China.”
The neurological drug research and development team of Prof. Jing Liang of the USC School of Pharmacy has established a new concept in pathogenesis of neurodegenerative diseases. In addition, the team has developed a new system of therapeutic compounds for Alzheimer’s disease. It has significant unique effects on prevention and treatment for the Alzheimer’s disease. This research has been published in top scientific journals and has been highly recognized by the International Alzheimer’s Association and the Royal College of Medicine. A new formulation of this newly developed drug for the prevention and treatment for Alzheimer’s dementia was filed with the US FDA. Prof. Jing Liang of the USC School of Pharmacy, said that she hopes to popularize the formulation to serve the Alzheimer’s dementia patients. The Center for Neurological Rehabilitation and Imaging in the University of Southern California has the top level neurological rehabilitation treatment and research system in the United States. Over the past three years, it has published over 6 world-class papers and has provided medical care for patients from all over the world. Freeze Holdings hopes to introduce these advanced systems for the treatment of Alzheimer’s disease to China as soon as possible.
Freeze Holdings was China’s first industry for low-carbon life. Freeze Holdings is committed to build an industry that focuses on five dimensions of life: water, air, food, safety, and human health. The Freeze Holdings owns 23 companies, including various sectors such as industrial funds, AI urban data, health, eco-agriculture and energy. The Freeze Holdings’ “Lifelong Appropriate” smart city system and artificial intelligence medical care platform have now been implement in many cities in China. In collaboration with the University of Southern California, School of Pharmacy and for the future operation of the China Center, Freeze Holdings will establish database on neurodegenerative disorders based on its own artificial intelligence data operation platform. Freeze Holdings will establish a complete network of regional Neuroscience Rehabilitation Centers and form an online and offline response system. At the same time, Freeze Holdings will, based on the domestic regional commercial layout, establish an ecological industry including Alzheimer’s disease medical intervention center, rehabilitation and nursing homes, drug research and development, product manufacture, professional rehabilitation training and planting.
The collaboration of Freeze Holdings and the University of Southern California will help and improve the brain health of Chinese elderly, accelerate industrialization of China’s elderly life services, allowing Chinese elderly people live “smart, healthy and happy”!
The Vice President of Freeze Holdings, Zhang Ke and others are at the office of Vassilios Papadopoulos, Dean of the University of Southern California School of Pharmacy
All person show victory sign, from left: Professor Dr. Jing Liang, Professor, School of Pharmaceutical Sciences, Southern California University of Medicine, Professor of Clinical Pharmacy, School of Pharmacy, Dr. Daryl L. Davies, Ph.D. Zhang Ke, Vice President of Freeze Holdings, Professor Vassilios Papadopoulos, Dean of the School of Pharmacy, Nangao University, and Yin Huixi, a medical and clinical consultant of Freeze Holdings and a famous Chinese cardiovascular and cerebrovascular specialist